# Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation

## Metadata
**Authors:** Venkateshwar Mutyam, Emily Falk Libby, Ning Peng, Denis Hadjiliadis, Michael Bonk, George M Solomon, Steven M Rowe
**Journal:** Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
**Date:** 2016 Oct 1
**DOI:** [10.1016/j.jcf.2016.09.005](https://doi.org/10.1016/j.jcf.2016.09.005)
**PMID:** 27707539
**PMCID:** PMC5241185
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241185/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC5241185/pdf/nihms-820598.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC5241185/pdf/nihms-820598.pdf)

## Abstract

Premature termination codons (PTCs) in cystic fibrosis transmembrane conductance regulator (CFTR) gene result in nonfunctional CFTR protein and are the proximate cause of ~11% of CF causing alleles. Aminoglycosides and other novel agents are known to induce translational readthrough of PTCs, a potential therapeutic approach. Among PTCs, W1282X CFTR is unique, as it is a C-terminal CFTR mutation that can exhibit partial activity, even in the truncated state. The potentiator ivacaftor (VX-770) is approved for treating CF patients with G551D and other gating mutations. Based on previous studies demonstrating beneficial effect of ivacaftor for PTC mutations following readthrough in vitro, we hypothesized that ivacaftor may enhance CFTR activity in CF patients expressing W1282X CFTR, and could be further enhanced by readthrough. Ivacaftor significantly increased CFTR activity in W1282X expressing cells compared to R1162X CFTR cells, and was further enhanced by readthrough with the aminoglycoside G418. Primary nasal epithelial cells from a W1282X homozygous patient showed improved CFTR function in the presence of ivacaftor. Upon ivacaftor administration to the same patient, there was significant improvement in pulmonary exacerbation frequency, BMI and, insulin requirement, whereas FEV1 remained stable over 3 years. These studies suggest that ivacaftor may have moderate clinical benefit in patients with preserved expression of the W1282X CFTR mutation by stimulating residual activity of the truncated protein, suggesting the need for further studies including the addition of efficacious readthrough agents.

Keywords: PTC mutations, W1282X, CFTR Potentiator, Ivacaftor, Readthrough

## Acknowledgements

The authors acknowledge the assistance of the CF patient who volunteered for this study and the dedicated individuals on her care team. We also acknowledge inspiration from Dr. Kevin Foskett.

Funding Source: NIH P30 DK072482, Emily's Entourage LLC, and the Cystic Fibrosis Foundation, each to S.M.R.

## Footnotes

## References

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992–2001. doi: 10.1056/NEJMra043184.  [DOI](https://doi.org/10.1056/NEJMra043184) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/15888700/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Cystic%20fibrosis.&author=SM%20Rowe&author=S%20Miller&author=EJ%20Sorscher&volume=352&publication_year=2005&pages=1992-2001&pmid=15888700&doi=10.1056/NEJMra043184&)

2. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73:1251–4. doi: 10.1016/0092-8674(93)90353-r.  [DOI](https://doi.org/10.1016/0092-8674(93)90353-r) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/7686820/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cell&title=Molecular%20mechanisms%20of%20CFTR%20chloride%20channel%20dysfunction%20in%20cystic%20fibrosis.&author=MJ%20Welsh&author=AE%20Smith&volume=73&publication_year=1993&pages=1251-4&pmid=7686820&doi=10.1016/0092-8674(93)90353-r&)

3. Rowe SM, Sloane P, Tang LP, Backer K, Mazur M, Buckley-Lanier J, Nudelman I, Belakhov V, Bebok Z, Schwiebert E, Baasov T, Bedwell DM. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J Mol Med (Berl) 2011 doi: 10.1007/s00109-011-0787-6.  [DOI](https://doi.org/10.1007/s00109-011-0787-6) | [PMC free article](/articles/PMC3204584/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21779978/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Mol%20Med%20(Berl)&title=Suppression%20of%20CFTR%20premature%20termination%20codons%20and%20rescue%20of%20CFTR%20protein%20and%20function%20by%20the%20synthetic%20aminoglycoside%20NB54.&author=SM%20Rowe&author=P%20Sloane&author=LP%20Tang&author=K%20Backer&author=M%20Mazur&publication_year=2011&pmid=21779978&doi=10.1007/s00109-011-0787-6&)

4. Rowe SM, Varga K, Rab A, Bebok Z, Byram K, Li Y, Sorscher EJ, Clancy JP. Restoration of W1282X CFTR Activity by Enhanced Expression. Am J Respir Cell Mol Biol. 2007;37:347–56. doi: 10.1165/rcmb.2006-0176OC.  [DOI](https://doi.org/10.1165/rcmb.2006-0176OC) | [PMC free article](/articles/PMC1994229/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17541014/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Respir%20Cell%20Mol%20Biol&title=Restoration%20of%20W1282X%20CFTR%20Activity%20by%20Enhanced%20Expression.&author=SM%20Rowe&author=K%20Varga&author=A%20Rab&author=Z%20Bebok&author=K%20Byram&volume=37&publication_year=2007&pages=347-56&pmid=17541014&doi=10.1165/rcmb.2006-0176OC&)

5. Sermet-Gaudelus I, Renouil M, Fajac A, Bidou L, Parbaille B, Pierrot S, Davy N, Bismuth E, Reinert P, Lenoir G, Lesure JF, Rousset JP, Edelman A. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med. 2007;5:5–14. doi: 10.1186/1741-7015-5-5.  [DOI](https://doi.org/10.1186/1741-7015-5-5) | [PMC free article](/articles/PMC1852113/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17394637/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMC%20Med&title=In%20vitro%20prediction%20of%20stop-codon%20suppression%20by%20intravenous%20gentamicin%20in%20patients%20with%20cystic%20fibrosis:%20a%20pilot%20study.&author=I%20Sermet-Gaudelus&author=M%20Renouil&author=A%20Fajac&author=L%20Bidou&author=B%20Parbaille&volume=5&publication_year=2007&pages=5-14&pmid=17394637&doi=10.1186/1741-7015-5-5&)

6. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, Kerem B, Kerem E. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349:1433–41. doi: 10.1056/NEJMoa022170.  [DOI](https://doi.org/10.1056/NEJMoa022170) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/14534336/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Gentamicin-induced%20correction%20of%20CFTR%20function%20in%20patients%20with%20cystic%20fibrosis%20and%20CFTR%20stop%20mutations.&author=M%20Wilschanski&author=Y%20Yahav&author=Y%20Yaacov&author=H%20Blau&author=L%20Bentur&volume=349&publication_year=2003&pages=1433-41&pmid=14534336&doi=10.1056/NEJMoa022170&)

7. Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med. 2000;161:860–5. doi: 10.1164/ajrccm.161.3.9904116.  [DOI](https://doi.org/10.1164/ajrccm.161.3.9904116) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/10712334/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Respir%20Crit%20Care%20Med&title=A%20pilot%20study%20of%20the%20effect%20of%20gentamicin%20on%20nasal%20potential%20difference%20measurements%20in%20cystic%20fibrosis%20patients%20carrying%20stop%20mutations.&author=M%20Wilschanski&author=C%20Famini&author=H%20Blau&author=J%20Rivlin&author=A%20Augarten&volume=161&publication_year=2000&pages=860-5&pmid=10712334&doi=10.1164/ajrccm.161.3.9904116&)

8. Clancy JP, Bebok Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M, Lyrene R, Sorscher EJ, Bedwell DM. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001;163:1683–92. doi: 10.1164/ajrccm.163.7.2004001.  [DOI](https://doi.org/10.1164/ajrccm.163.7.2004001) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/11401894/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Respir%20Crit%20Care%20Med&title=Evidence%20that%20systemic%20gentamicin%20suppresses%20premature%20stop%20mutations%20in%20patients%20with%20cystic%20fibrosis.&author=JP%20Clancy&author=Z%20Bebok&author=F%20Ruiz&author=C%20King&author=J%20Jones&volume=163&publication_year=2001&pages=1683-92&pmid=11401894&doi=10.1164/ajrccm.163.7.2004001&)

9. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med. 1997;3:1280–4. doi: 10.1038/nm1197-1280.  [DOI](https://doi.org/10.1038/nm1197-1280) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9359706/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat%20Med&title=Suppression%20of%20a%20CFTR%20premature%20stop%20mutation%20in%20a%20bronchial%20epithelial%20cell%20line.&author=DM%20Bedwell&author=A%20Kaenjak&author=DJ%20Benos&author=Z%20Bebok&author=JK%20Bubien&volume=3&publication_year=1997&pages=1280-4&pmid=9359706&doi=10.1038/nm1197-1280&)

10. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med. 1996;2:467–9. doi: 10.1038/nm0496-467.  [DOI](https://doi.org/10.1038/nm0496-467) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/8597960/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat%20Med&title=Aminoglycoside%20antibiotics%20restore%20CFTR%20function%20by%20overcoming%20premature%20stop%20mutations.&author=M%20Howard&author=RA%20Frizzell&author=DM%20Bedwell&volume=2&publication_year=1996&pages=467-9&pmid=8597960&doi=10.1038/nm0496-467&)

11. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J, Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106:18825–30. doi: 10.1073/pnas.0904709106.  [DOI](https://doi.org/10.1073/pnas.0904709106) | [PMC free article](/articles/PMC2773991/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19846789/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&title=Rescue%20of%20CF%20airway%20epithelial%20cell%20function%20in%20vitro%20by%20a%20CFTR%20potentiator,%20VX-770.&author=F%20Van%20Goor&author=S%20Hadida&author=PD%20Grootenhuis&author=B%20Burton&author=D%20Cao&volume=106&publication_year=2009&pages=18825-30&pmid=19846789&doi=10.1073/pnas.0904709106&)

12. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663–72. doi: 10.1056/NEJMoa1105185.  [DOI](https://doi.org/10.1056/NEJMoa1105185) | [PMC free article](/articles/PMC3230303/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22047557/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=A%20CFTR%20potentiator%20in%20patients%20with%20cystic%20fibrosis%20and%20the%20G551D%20mutation.&author=BW%20Ramsey&author=J%20Davies&author=NG%20McElvaney&author=E%20Tullis&author=SC%20Bell&volume=365&publication_year=2011&pages=1663-72&pmid=22047557&doi=10.1056/NEJMoa1105185&)

13. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordonez CL, Campbell PW, Ashlock MA, Ramsey BW. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363:1991–2003. doi: 10.1056/NEJMoa0909825.  [DOI](https://doi.org/10.1056/NEJMoa0909825) | [PMC free article](/articles/PMC3148255/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21083385/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&title=Effect%20of%20VX-770%20in%20persons%20with%20cystic%20fibrosis%20and%20the%20G551D-CFTR%20mutation.&author=FJ%20Accurso&author=SM%20Rowe&author=JP%20Clancy&author=MP%20Boyle&author=JM%20Dunitz&volume=363&publication_year=2010&pages=1991-2003&pmid=21083385&doi=10.1056/NEJMoa0909825&)

14. Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, Rowe SM. Network GIotCFFTD. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015;60:703–12. doi: 10.1093/cid/ciu944.  [DOI](https://doi.org/10.1093/cid/ciu944) | [PMC free article](/articles/PMC4342673/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/25425629/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&title=Network%20GIotCFFTD.%20Pseudomonas%20aeruginosa%20in%20cystic%20fibrosis%20patients%20with%20G551D-CFTR%20treated%20with%20ivacaftor.&author=SL%20Heltshe&author=N%20Mayer-Hamblett&author=JL%20Burns&author=U%20Khan&author=A%20Baines&volume=60&publication_year=2015&pages=703-12&pmid=25425629&doi=10.1093/cid/ciu944&)

15. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW. Clinical Mechanism of the CFTR Potentiator Ivacaftor in G551D-Mediated Cystic Fibrosis. Am J Respir Crit Care Med. 2014 doi: 10.1164/rccm.201404-0703OC.  [DOI](https://doi.org/10.1164/rccm.201404-0703OC) | [PMC free article](/articles/PMC4226057/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24927234/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Respir%20Crit%20Care%20Med&title=Clinical%20Mechanism%20of%20the%20CFTR%20Potentiator%20Ivacaftor%20in%20G551D-Mediated%20Cystic%20Fibrosis.&author=SM%20Rowe&author=SL%20Heltshe&author=T%20Gonska&author=SH%20Donaldson&author=D%20Borowitz&publication_year=2014&pmid=24927234&doi=10.1164/rccm.201404-0703OC&)

16. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP, Jr., Urrutia A, Joubran J, Seepersaud S, Sussky K, Hoffman BJ, Van Goor F. Ivacaftor potentiation of multiple CFTR channels with gating mutations. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2012;11:237–45. doi: 10.1016/j.jcf.2011.12.005.  [DOI](https://doi.org/10.1016/j.jcf.2011.12.005) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22293084/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Journal%20of%20cystic%20fibrosis%20:%20official%20journal%20of%20the%20European%20Cystic%20Fibrosis%20Society&title=Ivacaftor%20potentiation%20of%20multiple%20CFTR%20channels%20with%20gating%20mutations.&author=H%20Yu&author=B%20Burton&author=CJ%20Huang&author=J%20Worley&author=D%20Cao&volume=11&publication_year=2012&pages=237-45&pmid=22293084&doi=10.1016/j.jcf.2011.12.005&)

17. Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M, Group VXS. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015;3:524–33. doi: 10.1016/S2213-2600(15)00201-5.  [DOI](https://doi.org/10.1016/S2213-2600(15)00201-5) | [PMC free article](/articles/PMC4641035/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/26070913/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet%20Respir%20Med&title=Efficacy%20and%20safety%20of%20ivacaftor%20in%20patients%20with%20cystic%20fibrosis%20who%20have%20an%20Arg117His-CFTR%20mutation:%20a%20double-blind,%20randomised%20controlled%20trial.&author=RB%20Moss&author=PA%20Flume&author=JS%20Elborn&author=J%20Cooke&author=SM%20Rowe&volume=3&publication_year=2015&pages=524-33&pmid=26070913&doi=10.1016/S2213-2600(15)00201-5&)

18. Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13:29–36. doi: 10.1016/j.jcf.2013.06.008.  [DOI](https://doi.org/10.1016/j.jcf.2013.06.008) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23891399/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Cyst%20Fibros&title=Effect%20of%20ivacaftor%20on%20CFTR%20forms%20with%20missense%20mutations%20associated%20with%20defects%20in%20protein%20processing%20or%20function.&author=F%20Van%20Goor&author=H%20Yu&author=B%20Burton&author=BJ%20Hoffman&volume=13&publication_year=2014&pages=29-36&pmid=23891399&doi=10.1016/j.jcf.2013.06.008&)

19. Mutyam V, Du M, Xue X, Keeling KM, White EL, Bostwick JR, Rasmussen L, Liu B, Mazur M, Hong JS, Falk Libby E, Liang F, Shang H, Mense M, Suto MJ, Bedwell DM, Rowe SM. Discovery of Clinically Approved Agents That Promote Suppression of CFTR Nonsense Mutations. Am J Respir Crit Care Med. 2016 doi: 10.1164/rccm.201601-0154OC.  [DOI](https://doi.org/10.1164/rccm.201601-0154OC) | [PMC free article](/articles/PMC5114449/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/27104944/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Respir%20Crit%20Care%20Med&title=Discovery%20of%20Clinically%20Approved%20Agents%20That%20Promote%20Suppression%20of%20CFTR%20Nonsense%20Mutations.&author=V%20Mutyam&author=M%20Du&author=X%20Xue&author=KM%20Keeling&author=EL%20White&publication_year=2016&pmid=27104944&doi=10.1164/rccm.201601-0154OC&)

20. Xue X, Mutyam V, Tang L, Biswas S, Du M, Jackson LA, Dai Y, Belakhov V, Shalev M, Chen F, Schacht J, R JB, Baasov T, Hong J, Bedwell DM, Rowe SM. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol. 2014;50:805–16. doi: 10.1165/rcmb.2013-0282OC.  [DOI](https://doi.org/10.1165/rcmb.2013-0282OC) | [PMC free article](/articles/PMC4068923/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24251786/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Respir%20Cell%20Mol%20Biol&title=Synthetic%20aminoglycosides%20efficiently%20suppress%20cystic%20fibrosis%20transmembrane%20conductance%20regulator%20nonsense%20mutations%20and%20are%20enhanced%20by%20ivacaftor.&author=X%20Xue&author=V%20Mutyam&author=L%20Tang&author=S%20Biswas&author=M%20Du&volume=50&publication_year=2014&pages=805-16&pmid=24251786&doi=10.1165/rcmb.2013-0282OC&)

21. Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, Timofeeva OA, Nealon C, Dakic A, Simic V, Haddad BR, Rhim JS, Dritschilo A, Riegel A, McBride A, Schlegel R. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol. 2012;180:599–607. doi: 10.1016/j.ajpath.2011.10.036.  [DOI](https://doi.org/10.1016/j.ajpath.2011.10.036) | [PMC free article](/articles/PMC3349876/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22189618/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Pathol&title=ROCK%20inhibitor%20and%20feeder%20cells%20induce%20the%20conditional%20reprogramming%20of%20epithelial%20cells.&author=X%20Liu&author=V%20Ory&author=S%20Chapman&author=H%20Yuan&author=C%20Albanese&volume=180&publication_year=2012&pages=599-607&pmid=22189618&doi=10.1016/j.ajpath.2011.10.036&)
